Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas

Histology and Histopathology

Volumn 28, Issue 9, 2013, Pages 1157-1166

  Baumgarten, Peter ^a   Brokinkel, Benjamin ^b   Zinke, Jenny ^a   Zachskorn, Cornelia ^a   Ebel, Heinrich ^c   Albert, Friedrich K ^d   Stummer, Walter ^b   Plate, Karl H ^a   Harter, Patrick N ^a   Hasselblatt, Martin ^b   Mittelbronn, Michel ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c Department of Neurosurgery   (Germany)

^d Hospital Osnabrück   (Germany)

Author keywords

Bevacizumab; Malignant meningioma; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; PYRROLE DERIVATIVE; SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VEGFA PROTEIN, HUMAN;

AGED; ANOXIA; ARTICLE; BRAIN TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MENINGIOMA; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANOXIA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INDOLES; MALE; MENINGIOMA; MIDDLE AGED; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84884393628     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Barresi V. and Tuccari G. (2010). Increased ratio of vascular endothelial growth factor to semaphorin3A is a negative prognostic factor in human meningiomas. Neuropathology 30, 537-546.
2. Brokinkel B., Fischer B.R., Peetz-Dienhart S., Ebel H., Sepehrnia A., Rama B., Albert F.K., Stummer W., Paulus W. and Hasselblatt M. (2010). MGMT promoter methylation status in anaplastic meningiomas. J. Neurooncol. 100, 489-490.
3. Ding Y.S., Wang H.D., Tang K., Hu Z.G., Jin W. and Yan W. (2008). Expression of vascular endothelial growth factor in human meningiomas and peritumoral brain areas. Ann. Clin. Lab. Sci. 38, 344-351.
4. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., Chevreau C., Filipek M., Melichar B., Bajetta E., Gorbunova V., Bay J.O., Bodrogi I., Jagiello-Gruszfeld A., Moore N.; AVOREN Trial investigators. (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103-2111.
5. Ferrara N., Gerber H.P. and LeCouter J. (2003). The biology of VEGF and its receptors. Nat. Med. 9, 669-676.
6. Folkman J. (1971). Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186.
7. Gerber H.P., Condorelli F., Park J. and Ferrara N. (1997). Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J. Biol. Chem. 272, 23659-23667.
8. Goldman C.K., Bharara S., Palmer C.A., Vitek J., Tsai J.C., Weiss H.L. and Gillespie G.Y. (1997). Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. Neurosurgery 40, 1269-1277.
9. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R. and Kabbinavar F. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342.
10. Ilhan A., Gartner W., Neziri D., Czech T., Base W., Hörl W.H. and Wagner L. (2009). Angiogenic factors in plasma of brain tumour patients. Anticancer Res. 29, 731-736.
11. Jensen R.L., Soleau S., Bhayani M.K. and Christiansen D. (2002). Expression of hypoxia inducible factor-1 alpha and correlation with preoperative embolization of meningiomas. J. Neurosurg. 97, 658-667.
12. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J. and Connolly D.T. (1989). Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246, 1309-1312.
13. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S. and Ferrara N. (1993). Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844.
14. Koch S., Tugues S., Li X., Gualandi L. and Claesson-Welsh L. (2011). Signal transduction by vascular endothelial growth factor receptors. Biochem. J. 437, 169-183.
15. Lamszus K., Lengler U., Schmidt N.O., Stavrou D., Ergun S. and Westphal M. (2000). Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 46, 938-947.
16. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V. and Ferrara N. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309.
17. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W. and Kleihues P. (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97-109.
18. Maiuri F., De Caro M.B., Esposito F., Cappabianca P., Strazzullo V., Pettinato G. and de Divitiis E. (2007). Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. J. Neurooncol. 82, 63-68.
19. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., Shenkier T., Cella D. and Davidson N.E. (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676.
20. Modha A. and Gutin P.H. (2005). Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 57, 538-550.
21. Nassehi D., Dyrbye H., Andresen M., Thomsen C., Juhler M., Laursen H. and Broholm H. (2011). Vascular endothelial growth factor A protein level and gene expression in intracranial meningiomas with brain edema. APMIS. 119, 831-843.
22. Nayak L., Iwamoto F.M., Rudnick J.D., Norden A.D., Lee E.Q., Drappatz J., Omuro A. and Kaley T.J. (2012) Atypical and anaplastic meningiomas treated with bevacizumab. J. Neurooncol. 109, 187-193.
23. Otsuka S., Tamiya T., Ono Y., Michiue H., Kurozumi K., Daido S., Kambara H., Date I. and Ohmoto T. (2004). The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas. J. Neurooncol. 70, 349-357.
24. Panagopoulos A.T., Lancellotti C.L., Veiga J.C., de Aguiar P.H. and Colquhoun A. (2008). Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J. Neurooncol. 89, 73-87.
25. Perry A., Scheithauer B.W., Stafford S.L., Lohse C.M. and Wollan P.C. (1999). Malignancy in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 85, 2046-2056.
26. Pietsch T., Valter M.M., Wolf H.K., von Deimling A., Huang H.J., Cavenee W.K. and Wiestler O.D. (1997). Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol. 93, 109-117.
27. Pistolesi S., Fontanini G., Camacci T., De Ieso K., Boldrini L., Lupi G., Padolecchia R., Pingitore R. and Parenti G. (2002). Meningiomaassociated brain oedema: the role of angiogenic factors and pial blood supply. J. Neurooncol. 60, 159-164.
28. Plate K.H., Breier G., Weich H.A. and Risau W. (1992). Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359, 845-848.
29. Platt S.R., Scase T.J., Adams V., Wieczorek L., Miller J., Adamo F. and Long S. (2006). Vascular endothelial growth factor expression in canine intracranial meningiomas and association with patient survival. J. Vet. Intern. Med. 20, 663-668.
30. Ryan H.E., Lo J. and Johnson R.S. (1998). HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17, 3005-3015.
31. Sakuma T., Nakagawa T., Ido K., Takeuchi H., Sato K. and Kubota T. (2008). Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human meningiomas. J. Neurooncol. 88, 143-155.
32. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R. and Johnson D.H. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550.
33. Schmid S., Aboul-Enein F., Pfisterer W., Birkner T., Stadek C. and Knosp E. (2010). Vascular endothelial growth factor: the major factor for tumor neovascularization and edema formation in meningioma patients. Neurosurgery 67, 1703-1708.
34. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S. and Dvorak H.F. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985.
35. Shibuya M. (2006). Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9, 225-230.
36. Shweiki D., Itin A., Soffer D. and Keshet E. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845.
37. Ulyatt C., Walker J. and Ponnambalam S. (2011). Hypoxia differentially regulates VEGFR1 and VEGFR2 levels and alters intracellular signaling and cell migration in endothelial cells. Biochem. Biophys. Res. Commun. 404, 774-779.
38. Wilting J., Christ B. and Weich H.A. (1992). The effects of growth factors on the day 13 chorioallantoic membrane (CAM): a study of VEGF165 and PDGF-BB. Anat. Embryol. 186, 251-257.
39. Zhang Z., Neiva K.G., Lingen M.W., Ellis L.M. and Nör J.E. (2010a) VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell. Death. Differ. 17, 499-512.
40. Zhang M.X., Zhao X., Wang Z.G., Zhao W.M. and Wang Y.S. (2010b). Constitutive activation of signal transducer and activator of transcription 3 regulates expression of vascular endothelial growth factor in human meningioma differentiation. J. Cancer Res. Clin. Oncol. 136, 981-988.